FDA.reportPublic FDA data

CROSPOVIDONE, UNSPECIFIED

Substance profile for UNII 2S7830E561, enriched with FDA NDC listings, DailyMed labels, legacy aliases, and open chemistry identifiers.

Substance Identity#

UNII
2S7830E561
Preferred term
CROSPOVIDONE, UNSPECIFIED
Registry number
9003-39-8
Ingredient type
UNSPECIFIED INGREDIENT

Chemical And Database Identifiers#

RxCUI
1310706
PubChem
0
NCIt
C80893
INN ID
4559

Open Chemistry Sources#

Source, Identifier, Link table
SourceIdentifierLink
RxNorm1310706mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1310706
NCI ThesaurusC80893ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C80893
FDA Substance Registration System2S7830E561precision.fda.gov/uniisearch/srs/unii/2S7830E561

Inactive Ingredient Database#

Browse recovered IID releases and source provenance.

Current IID rows for UNII 2S7830E561 page 1 of 1 ยท 33 matching rows.

Ingredient, UNII, CAS table
IngredientUNIICASDosage formRoutePotencyMaximum daily exposure
CROSPOVIDONE2S7830E5619003398INJECTIONINTRAVENOUS1.4 mg
CROSPOVIDONE2S7830E5619003398SOLUTIONOPHTHALMIC3 %w/w
CROSPOVIDONE2S7830E5619003398CAPSULEORAL250 mg
CROSPOVIDONE2S7830E5619003398CAPSULE, COATED, EXTENDED RELEASEORALNA
CROSPOVIDONE2S7830E5619003398CAPSULE, DELAYED RELEASEORAL365 mg
CROSPOVIDONE2S7830E5619003398CAPSULE, EXTENDED RELEASEORAL25.1 mg
CROSPOVIDONE2S7830E5619003398GRANULEORAL238 mg
CROSPOVIDONE2S7830E5619003398GRANULE, FOR SOLUTIONORAL36.3 mg/120ml
CROSPOVIDONE2S7830E5619003398GRANULE, FOR SUSPENSIONORAL810 mg
CROSPOVIDONE2S7830E5619003398PELLETORAL28 mg
CROSPOVIDONE2S7830E5619003398SUSPENSIONORAL114 mg
CROSPOVIDONE2S7830E5619003398SUSPENSION, EXTENDED RELEASEORAL186.8 mg
CROSPOVIDONE2S7830E5619003398TABLETORAL2352 mg
CROSPOVIDONE2S7830E5619003398TABLET, CHEWABLEORAL300 mg
CROSPOVIDONE2S7830E5619003398TABLET, CHEWABLE, EXTENDED RELEASEORAL90 mg
CROSPOVIDONE2S7830E5619003398TABLET, COATEDORAL208 mg
CROSPOVIDONE2S7830E5619003398TABLET, DELAYED RELEASEORAL336 mg
CROSPOVIDONE2S7830E5619003398TABLET, EXTENDED RELEASEORAL624 mg
CROSPOVIDONE2S7830E5619003398TABLET, FILM COATEDORAL787 mg
CROSPOVIDONE2S7830E5619003398TABLET, FILM COATED, EXTENDED RELEASEORAL24 mg
CROSPOVIDONE2S7830E5619003398TABLET, FOR SUSPENSIONORAL1733 mg
CROSPOVIDONE2S7830E5619003398TABLET, ORALLY DISINTEGRATINGORAL1260 mg
CROSPOVIDONE2S7830E5619003398TABLET, ORALLY DISINTEGRATING, DELAYED RELEASEORAL660 mg
CROSPOVIDONE2S7830E5619003398WAFERORAL97 mg
CROSPOVIDONE2S7830E5619003398PELLETSUBCUTANEOUS2 mg
CROSPOVIDONE2S7830E5619003398TABLETSUBLINGUAL60 mg
CROSPOVIDONE2S7830E5619003398EMULSIONTOPICAL1 %w/w
CROSPOVIDONE2S7830E5619003398LOTIONTOPICAL0.5 %w/w
CROSPOVIDONE2S7830E5619003398FILMTRANSDERMAL4 mg
CROSPOVIDONE2S7830E5619003398FILM, EXTENDED RELEASETRANSDERMAL60 mg
CROSPOVIDONE2S7830E5619003398SYSTEMTRANSDERMAL286 mg
CROSPOVIDONE2S7830E5619003398AEROSOL, FOAMVAGINAL1 %w/w
CROSPOVIDONE2S7830E5619003398SUPPOSITORYVAGINAL116.1 mg